3 ms·
Insurance companies are the real target here. If they can potentially manage to get doctors to prescribe more efficient medication, then they will end up needin
by yoz-y 6y ago
Insurance companies are the real target here. If they can potentially manage to get doctors to prescribe more efficient medication, then they will end up needing to reimburse less and improve their bottom line.
- nextos 6y agoExactly. Some 23andme clones are aiming at insurance companies and national healthcare systems. I know at least two of them personally, with investments from big pharma. If you convince say, NHS, that this service would make their medical practice more efficient they would totally buy it! For this you'd need to hire MDs and play lots of regulatory tricks. Plus, after that, probably private medical offices would follow the lead. Companies doing genetics-based prediction are trying to fight the same uphill battle, and I think it's one worth fighting. So don't give up!